Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature currently requires accessing the site using the built-in Safari browser.
You are using an out of date browser. It may not display this or other websites correctly. You should upgrade or use an alternative browser.
Fri news: Gilead withdraws bladder cancer drug. Amgen and Intercept PDUFA date pushback. CVS replaces CEO. Supernus depression trial. AbbVie Parkinson’s approval. See more on our front page
Too true!! All me too products and life cycle management under Brennan. He made his name by stringing along the lost sales of Prilosec with Nexium. But that is a short term game. He was anti-innovation when it came to investment. He is indeed a classic example of the Peter Principle. They have it half right on Medimmune too. It was already a nearly empty shell when AZ bought it like suckers. TZ and RF did really finish the job on it though.
A quote from the article, "As it turned out, with Brennan out of the country, AZ's managers took close control over MedImmune, thereby strangling biotech innovation with Big Pharma's finance control. MedImmune's top scientists and managers soon departed and within the past year, AZ's major shareholders in London started complaining publicly that they have nothing to show for their $15 billion purchase."
Everyone knows our managers are total idiots, including this reporter! They "strangle" every damn thing they touch! Brennan was a cancer, that unfortunately has killed the patient known as AZ!
With Medimmune, everything was just for show just like always. Look everyone at how innovative AZ is moving into in biotech now!! Then it was bled dry just like everything else, so they could line their pockets some more.